Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

    Reason given in the registry

    “The sponsor is no longer supporting the drug”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04582864
  2. Withdrawn

    Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.

    Ended
    Jun 2026
    Phase
    Phase 1
    Run by
    Leland Metheny
    Registry record
    NCT03939585
  3. Terminated

    Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

    Reason given in the registry

    “Lack of Enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Nov 2024.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Hackensack Meridian Health
    Registry record
    NCT02846376
  4. Withdrawn

    Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Difficulty in joining the group”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2024.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Beijing Boren Hospital
    Registry record
    NCT05266950
  5. Withdrawn

    Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

    Reason given in the registry

    “Could not accrue”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2024.

    Phase
    Phase 1/2
    Run by
    Guenther Koehne
    Registry record
    NCT04982354
  6. Withdrawn

    Tislelizumab with Azacitidine in the Treatment of R/R AML

    Reason given in the registry

    “withdrawn”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Jun 2025
    Phase
    Phase 1/2
    Run by
    Institute of Hematology & Blood Diseases Hospital, China
    Registry record
    NCT06586099
  7. Terminated

    Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Jul 2024
    Phase
    Phase 1/2
    Run by
    K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
    Registry record
    NCT05682170
  8. Withdrawn

    Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

    Reason given in the registry

    “Withdrawn -ctms”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Feb 2026
    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT05823480
  9. Withdrawn

    CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “PI decided not to move forward with the study”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT05854966
  10. Withdrawn

    Antimicrobial Revision in Persistent Febrile Neutropenia

    Reason given in the registry

    “Study was never initiated or activated - Reason was lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Apr 2025
    Phase
    Phase 4
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT05784844
  11. Terminated

    A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

    Reason given in the registry

    “A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2024.

    Ended
    Jul 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT03530683
  12. Terminated

    Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

    Reason given in the registry

    “On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2024.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Malika Kapadia
    Registry record
    NCT05569512
  13. Withdrawn

    Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Sponsor withdrew support.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2024.

    Phase
    Phase 1
    Run by
    Medical College of Wisconsin
    Registry record
    NCT06007911
  14. Terminated

    A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.

    Ended
    Apr 2024
    Phase
    Phase 1/2
    Run by
    Kronos Bio
    Registry record
    NCT05028751
  15. Withdrawn

    ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

    Reason given in the registry

    “Lack of Funding - no safety issue with Drug; Company Permanently Closed”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    Elucida Oncology
    Registry record
    NCT05622591
  16. Terminated

    Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Trial failed to meet primary endpoint.”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2024.

    Ended
    Mar 2024
    Phase
    Phase 3
    Run by
    GlycoMimetics Incorporated
    Registry record
    NCT03616470
  17. Terminated

    Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Resources related issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jul 2024.

    Ended
    May 2024
    Run by
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT04920188
  18. Withdrawn

    Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

    Reason given in the registry

    “Unable to accommodate FDA recommendations for protocol revisions”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jun 2024.

    Phase
    Phase 2
    Run by
    Northside Hospital, Inc.
    Registry record
    NCT06337331
  19. Terminated

    A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

    Reason given in the registry

    “Business objectives have changed.”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 May 2024.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Celgene
    Registry record
    NCT04336982
  20. Withdrawn

    Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

    Reason given in the registry

    “investigator's unavailability”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2024.

    Ended
    Dec 2024
    Run by
    Centre Hospitalier Régional Metz-Thionville
    Registry record
    NCT05309018
  21. Withdrawn

    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

    Reason given in the registry

    “PI has left IU with no plan to initiate study at IU”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Apr 2024.

    Ended
    Dec 2025
    Phase
    Phase 1/2
    Run by
    Indiana University
    Registry record
    NCT05895201
  22. Withdrawn

    A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review

    Reason given in the registry

    “Strategic considerations”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Apr 2024.

    Ended
    Apr 2024
    Run by
    AbbVie
    Registry record
    NCT06362031
  23. Withdrawn

    A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

    Reason given in the registry

    “waiting for update from Study Lead”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Apr 2024.

    Phase
    Phase 1/2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT05367401
  24. Withdrawn

    Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

    Reason given in the registry

    “trial was not opened”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Mar 2024.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    Jonsson Comprehensive Cancer Center
    Registry record
    NCT05720988
  25. Terminated

    A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

    Reason given in the registry

    “The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Feb 2024.

    Ended
    Feb 2024
    Phase
    Phase 1
    Run by
    Hemavant Sciences GmbH
    Registry record
    NCT02841540
  26. Terminated

    Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Discontinued”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.

    Ended
    Dec 2023
    Phase
    Phase 1/2
    Run by
    CicloMed LLC
    Registry record
    NCT04956042
  27. Withdrawn

    Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

    Reason given in the registry

    “Trial was stopped prematurely due to safety reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.

    Phase
    Phase 2
    Run by
    Uwe Platzbecker
    Registry record
    NCT05829434
  28. Terminated

    PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

    Reason given in the registry

    “Company Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.

    Ended
    Jan 2024
    Phase
    Phase 1
    Run by
    Prelude Therapeutics Incorporated
    Registry record
    NCT05107856
  29. Suspended

    A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

    Reason given in the registry

    “Prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jan 2024.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Syros Pharmaceuticals
    Registry record
    NCT04996030
  30. Withdrawn

    Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

    Reason given in the registry

    “Lack of funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2023.

    Phase
    Phase 2
    Run by
    Yale University
    Registry record
    NCT06180863

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.